Northwire Canada EditionFriday, July 10, 2026
Northwire
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Earnings Routine +

Vext Reports Q4 and FY 2025; Fiscal 2025 Revenue up +43% to $51.4M, Operating Cash Flow up +256% to $11.7M as Ohio Retail Scales

Vext Cash Flow Turnaround Meets Tax Reality Check

Executive Summary
  • Event: Vext Science reported Fiscal 2025 (ended Dec 31, 2025) and Q4 2025 financial results on April 29, 2026.
  • Financial Highlights:
    • Revenue: $51.4 million (+43% YoY).
    • Operating Cash Flow (OCF): $11.7 million (+256% YoY).
    • Adjusted EBITDA: $10.9 million for FY 2025; Q4 Adjusted EBITDA was $2.1 million.
    • Reported Q4 EBITDA: -$3.0 million (impacted by a $5.0 million non-cash impairment on a Columbus, Ohio dispensary).
  • Operational Strategy:
    • Ohio: Expanding retail footprint from 5 to 8 dispensaries (state cap) by early 2027. Currently operating 5 locations.
    • Arizona: Exiting cultivation at Eloy facility; redeploying equipment to Jackson, Ohio to save ~$2 million CAPEX. Proceeds from sale to pay down mortgage debt.
  • Accounting Adjustments & Liabilities:
    • Inventory valuation methodology reassessed (FY 2024 amortization adjusted by $2.9 million).
    • Prepaid assets reclassified (Big Perm Dispensaries acquisition deposits moved to non-current).
    • Uncertain Tax Position (UTP) liabilities recognized: $5.5 million for 2023 and $7.7 million for 2024.
Material Impact
  • Positive Factors: The company has successfully transitioned from cash burn to positive operating cash flow ($11.7M), validating the strategic pivot announced in March 2026 regarding Arizona optimization and Ohio expansion. Revenue growth of 43% demonstrates top-line momentum in key markets.
  • Negative/Risk Factors:
    • Impairment Charge: The $5.0 million impairment on a Columbus dispensary suggests potential overvaluation of assets or slower-than-expected ramp-up at that specific location, impacting reported EBITDA negatively for the quarter.
    • Tax Liabilities: The recognition of $7.7 million in UTP liabilities for 2024 is a significant balance sheet revelation not fully detailed in prior operational updates. This represents a potential cash outflow or equity reduction that offsets some of the operating cash flow gains.
    • Accounting Restatements: Inventory and prepaid asset adjustments indicate previous accounting methodologies may have been aggressive, requiring scrutiny on future financial reporting quality.
  • Conclusion: While the operational turnaround (OCF) is positive, the accounting adjustments and tax liabilities introduce risk that prevents this from being classified as "Material - Positive" in a risk-averse context. It confirms the March strategy but adds hidden cost layers.
VEXT · Price
Company Overview
  • Overview: Vext Science operates as a vertically integrated cannabis company with a focus on retail and cultivation in Ohio and Arizona.
  • Flagship Project: The "Herbal Wellness Centers" retail network in Ohio is the primary growth driver, targeting the state's eight-dispensary license cap.
  • Development Status: Currently operating 5 of 8 licensed locations in Ohio. Expansion plans include 3 additional stores by early 2027. Arizona operations are being optimized (cultivation exit) to focus capital on Ohio retail margins.
Read the original news release →

More from Vext Science Inc.